IARC group 2B
IARC Group 2B
The International Agency for Research on Cancer (IARC) classifies agents, mixtures, and exposures into different groups based on their carcinogenic risk to humans. IARC Group 2B is a classification used to denote agents that are "possibly carcinogenic to humans." This classification is used when there is limited evidence of carcinogenicity in humans and less than sufficient evidence in experimental animals.
Criteria for Classification[edit | edit source]
The classification into Group 2B is based on the following criteria:
- Limited evidence of carcinogenicity in humans: This means that a positive association has been observed between exposure to the agent and cancer, but other explanations for the observations (such as chance, bias, or confounding) could not be ruled out.
- Less than sufficient evidence of carcinogenicity in experimental animals: This indicates that the evidence from animal studies is not strong enough to classify the agent as a probable carcinogen (Group 2A).
Examples of Group 2B Agents[edit | edit source]
Some examples of agents classified as Group 2B include:
- Radiofrequency electromagnetic fields: These are emitted by wireless communication devices such as mobile phones.
- Lead: Exposure to lead and lead compounds has been associated with various health risks, including potential carcinogenic effects.
- Coffee: Previously classified as Group 2B, coffee has been re-evaluated and is no longer considered a possible carcinogen.
Implications of Group 2B Classification[edit | edit source]
The classification of an agent as Group 2B does not mean that it is a definite cause of cancer. Instead, it indicates that there is some evidence suggesting a potential risk, and further research is needed to clarify the relationship between the agent and cancer.
Research and Evaluation Process[edit | edit source]
The IARC Monographs program is responsible for evaluating the carcinogenic risks of various agents. The evaluation process involves:
1. Review of scientific literature: Comprehensive review of available studies on the agent. 2. Assessment of evidence: Evaluation of the quality and strength of the evidence. 3. Expert panel discussions: Involvement of international experts to discuss and reach a consensus on the classification.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
